GTHX Research Development vs Interest Income Analysis

GTHX Stock

USD 4.49 0.05 1.13%

G1 Therapeutics financial indicator trend analysis is much more than just examining G1 Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether G1 Therapeutics is a good investment. Please check the relationship between G1 Therapeutics Research Development and its Interest Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in G1 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.

Research Development vs Interest Income

Research Development vs Interest Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of G1 Therapeutics Research Development account and Interest Income. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between G1 Therapeutics' Research Development and Interest Income is -0.03. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Interest Income in the same time period over historical financial statements of G1 Therapeutics, assuming nothing else is changed. The correlation between historical values of G1 Therapeutics' Research Development and Interest Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of G1 Therapeutics are associated (or correlated) with its Interest Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Income has no effect on the direction of Research Development i.e., G1 Therapeutics' Research Development and Interest Income go up and down completely randomly.

Correlation Coefficient

-0.03

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Research Development

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Most indicators from G1 Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into G1 Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in G1 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.Selling General Administrative is likely to drop to about 46.9 M in 2024. Tax Provision is likely to drop to about 1.9 M in 2024

G1 Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Common Stock Total Equity	Property Plant And Equipment Gross	Treasury Stock	Other Liab	Retained Earnings Total Equity	Capital Surpluse
Total Assets		0.61	0.7	-0.66	0.95	0.69	-0.81	-0.59	0.67	0.93	0.69	0.79	0.99	0.78	0.53	0.17	0.52	1.0	0.8	0.55	0.81	0.68	0.06	0.59	-0.54	0.72
Other Current Liab	0.61		0.92	-0.27	0.44	0.69	-0.14	-0.88	0.8	0.38	0.67	0.3	0.52	0.85	0.74	0.66	0.92	0.6	0.86	0.41	0.86	0.77	0.45	0.82	-0.88	0.89
Total Current Liabilities	0.7	0.92		-0.4	0.53	0.82	-0.23	-0.93	0.88	0.47	0.82	0.48	0.61	0.93	0.85	0.63	0.94	0.68	0.94	0.42	0.94	0.88	0.41	0.92	-0.93	0.94
Total Stockholder Equity	-0.66	-0.27	-0.4		-0.61	-0.66	0.66	0.26	-0.12	-0.73	-0.69	-0.78	-0.66	-0.43	-0.61	0.37	-0.37	-0.65	-0.39	-0.44	-0.39	-0.6	0.22	-0.52	0.27	-0.41
Net Tangible Assets	0.95	0.44	0.53	-0.61		0.58	-0.86	-0.43	0.5	0.92	0.57	0.71	0.96	0.61	0.34	0.07	0.31	0.95	0.72	0.56	0.72	0.55	0.06	0.45	-0.36	0.59
Property Plant And Equipment Net	0.69	0.69	0.82	-0.66	0.58		-0.37	-0.73	0.62	0.55	1.0	0.48	0.63	0.78	0.72	0.29	0.71	0.67	0.76	0.77	0.76	0.99	0.2	0.93	-0.74	0.78
Net Debt	-0.81	-0.14	-0.23	0.66	-0.86	-0.37		0.02	-0.28	-0.96	-0.37	-0.8	-0.86	-0.37	-0.1	0.38	-0.02	-0.82	-0.4	-0.47	-0.41	-0.3	0.33	-0.16	-0.03	-0.24
Retained Earnings	-0.59	-0.88	-0.93	0.26	-0.43	-0.73	0.02		-0.78	-0.28	-0.73	-0.28	-0.5	-0.88	-0.81	-0.8	-0.9	-0.58	-0.87	-0.34	-0.88	-0.81	-0.63	-0.87	0.99	-0.95
Accounts Payable	0.67	0.8	0.88	-0.12	0.5	0.62	-0.28	-0.78		0.46	0.61	0.43	0.6	0.83	0.56	0.65	0.75	0.66	0.84	0.36	0.85	0.67	0.25	0.68	-0.75	0.75
Cash	0.93	0.38	0.47	-0.73	0.92	0.55	-0.96	-0.28	0.46		0.55	0.86	0.95	0.57	0.35	-0.19	0.28	0.93	0.6	0.51	0.6	0.5	-0.21	0.38	-0.23	0.47
Non Current Assets Total	0.69	0.67	0.82	-0.69	0.57	1.0	-0.37	-0.73	0.61	0.55		0.51	0.63	0.77	0.76	0.27	0.72	0.67	0.75	0.74	0.76	0.99	0.18	0.93	-0.74	0.78
Non Currrent Assets Other	0.79	0.3	0.48	-0.78	0.71	0.48	-0.8	-0.28	0.43	0.86	0.51		0.8	0.58	0.56	-0.22	0.37	0.79	0.52	0.2	0.53	0.44	-0.24	0.37	-0.25	0.41
Cash And Short Term Investments	0.99	0.52	0.61	-0.66	0.96	0.63	-0.86	-0.5	0.6	0.95	0.63	0.8		0.71	0.44	0.09	0.42	1.0	0.73	0.54	0.74	0.6	0.0	0.5	-0.45	0.64
Common Stock Shares Outstanding	0.78	0.85	0.93	-0.43	0.61	0.78	-0.37	-0.88	0.83	0.57	0.77	0.58	0.71		0.77	0.56	0.81	0.77	0.91	0.47	0.92	0.82	0.47	0.85	-0.84	0.92
Other Current Assets	0.53	0.74	0.85	-0.61	0.34	0.72	-0.1	-0.81	0.56	0.35	0.76	0.56	0.44	0.77		0.39	0.91	0.51	0.72	0.17	0.72	0.78	0.32	0.85	-0.84	0.81
Other Stockholder Equity	0.17	0.66	0.63	0.37	0.07	0.29	0.38	-0.8	0.65	-0.19	0.27	-0.22	0.09	0.56	0.39		0.62	0.16	0.6	0.06	0.6	0.4	0.74	0.51	-0.78	0.65
Total Liab	0.52	0.92	0.94	-0.37	0.31	0.71	-0.02	-0.9	0.75	0.28	0.72	0.37	0.42	0.81	0.91	0.62		0.51	0.8	0.23	0.8	0.79	0.37	0.87	-0.94	0.89
Total Current Assets	1.0	0.6	0.68	-0.65	0.95	0.67	-0.82	-0.58	0.66	0.93	0.67	0.79	1.0	0.77	0.51	0.16	0.51		0.79	0.54	0.8	0.66	0.06	0.57	-0.53	0.71
Common Stock	0.8	0.86	0.94	-0.39	0.72	0.76	-0.4	-0.87	0.84	0.6	0.75	0.52	0.73	0.91	0.72	0.6	0.8	0.79		0.47	1.0	0.81	0.47	0.84	-0.83	0.93
Property Plant Equipment	0.55	0.41	0.42	-0.44	0.56	0.77	-0.47	-0.34	0.36	0.51	0.74	0.2	0.54	0.47	0.17	0.06	0.23	0.54	0.47		0.47	0.72	0.07	0.58	-0.31	0.42
Common Stock Total Equity	0.81	0.86	0.94	-0.39	0.72	0.76	-0.41	-0.88	0.85	0.6	0.76	0.53	0.74	0.92	0.72	0.6	0.8	0.8	1.0	0.47		0.81	0.47	0.84	-0.83	0.93
Property Plant And Equipment Gross	0.68	0.77	0.88	-0.6	0.55	0.99	-0.3	-0.81	0.67	0.5	0.99	0.44	0.6	0.82	0.78	0.4	0.79	0.66	0.81	0.72	0.81		0.3	0.97	-0.82	0.85
Treasury Stock	0.06	0.45	0.41	0.22	0.06	0.2	0.33	-0.63	0.25	-0.21	0.18	-0.24	0.0	0.47	0.32	0.74	0.37	0.06	0.47	0.07	0.47	0.3		0.44	-0.56	0.57
Other Liab	0.59	0.82	0.92	-0.52	0.45	0.93	-0.16	-0.87	0.68	0.38	0.93	0.37	0.5	0.85	0.85	0.51	0.87	0.57	0.84	0.58	0.84	0.97	0.44		-0.89	0.9
Retained Earnings Total Equity	-0.54	-0.88	-0.93	0.27	-0.36	-0.74	-0.03	0.99	-0.75	-0.23	-0.74	-0.25	-0.45	-0.84	-0.84	-0.78	-0.94	-0.53	-0.83	-0.31	-0.83	-0.82	-0.56	-0.89		-0.94
Capital Surpluse	0.72	0.89	0.94	-0.41	0.59	0.78	-0.24	-0.95	0.75	0.47	0.78	0.41	0.64	0.92	0.81	0.65	0.89	0.71	0.93	0.42	0.93	0.85	0.57	0.9	-0.94

Click cells to compare fundamentals

G1 Therapeutics Account Relationship Matchups

G1 Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	284.8M	228.6M	254.1M	188.0M	121.5M	179.2M
Other Current Liab	15.4M	3.1M	23.6M	27.0M	23.8M	12.5M
Total Current Liabilities	19.8M	23.4M	27.6M	35.6M	29.7M	18.5M
Total Stockholder Equity	(336.9M)	(436.1M)	(584.5M)	68.7M	35.4M	37.2M
Net Tangible Assets	255.5M	177.4M	143.5M	68.7M	79.1M	121.0M
Property Plant And Equipment Net	13.4M	10.5M	9.0M	8.0M	6.4M	5.4M
Net Debt	(259.0M)	(179.5M)	(138.1M)	(10.8M)	24.9M	26.1M
Retained Earnings	(336.9M)	(436.1M)	(584.5M)	(732.0M)	(780.0M)	(741.0M)
Accounts Payable	3.7M	3.6M	2.9M	7.4M	4.0M	3.6M
Cash	269.2M	207.3M	221.2M	94.6M	32.3M	30.7M
Non Current Assets Total	13.8M	12.2M	10.5M	8.5M	6.6M	5.9M
Non Currrent Assets Other	437K	1.2M	1.2M	264K	21K	20.0K
Cash And Short Term Investments	269.2M	207.3M	221.2M	145.1M	82.2M	161.9M
Common Stock Shares Outstanding	37.5M	37.9M	41.9M	43.6M	51.7M	33.7M
Other Current Assets	1.8M	8.8M	13.2M	7.1M	7.6M	4.6M
Other Stockholder Equity	222.7M	318K	(4K)	800.8M	815.4M	856.1M
Total Liab	29.3M	51.2M	110.6M	119.2M	86.2M	47.2M
Total Current Assets	271.0M	216.4M	243.6M	179.5M	114.9M	173.3M
Property Plant Equipment	13.4M	2.5M	2.0M	2.0M	2.3M	2.7M
Liabilities And Stockholders Equity	(307.5M)	(384.9M)	(473.9M)	188.0M	121.5M	127.6M
Property Plant And Equipment Gross	13.4M	10.5M	10.3M	9.8M	8.7M	6.7M
Non Current Liabilities Total	9.5M	27.8M	82.9M	83.6M	56.4M	35.8M
Non Current Liabilities Other	9.5M	7.9M	6.8M	5.6M	41K	39.0K
Retained Earnings Total Equity	(336.9M)	(436.1M)	(584.5M)	(732.0M)	(658.8M)	(625.9M)
Capital Surpluse	592.4M	613.5M	728.0M	800.8M	920.9M	647.2M
Net Invested Capital	255.5M	197.2M	218.7M	145.8M	86.9M	155.0M
Net Working Capital	251.2M	192.9M	216.0M	143.9M	85.2M	153.1M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards G1 Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, G1 Therapeutics' short interest history, or implied volatility extrapolated from G1 Therapeutics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether G1 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of G1 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of G1 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on G1 Therapeutics Stock:

How To Invest In GTHX

Details

Is GTHX Stock a good investment?

Details

What is G1 Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in G1 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.

Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.

Complementary Tools for GTHX Stock analysis

When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets

Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know GTHX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.93)

Revenue Per Share

1.62

Quarterly Revenue Growth

0.118

Return On Assets

(0.16)

Return On Equity

(0.92)

The market value of G1 Therapeutics is measured differently than its book value, which is the value of GTHX that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GTHX Research Development vs Interest Income Analysis

Research Development vs Interest Income

Research Development vs Interest Income Correlation Analysis

Correlation Coefficient

Research Development

Interest Income

G1 Therapeutics fundamental ratios Correlations

G1 Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

G1 Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for GTHX Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock Total Equity	+ 1.0	Common Stock
Cash And Short Term Investments	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net

Cash	- 0.96	Net Debt
Capital Surpluse	- 0.95	Retained Earnings
Capital Surpluse	- 0.94	Retained Earnings Total Equity
Retained Earnings Total Equity	- 0.94	Total Liab
Retained Earnings Total Equity	- 0.93	Total Current Liabilities
Retained Earnings	- 0.93	Total Current Liabilities